Skip to main content
Erschienen in: Cancer Causes & Control 8/2011

01.08.2011 | Original paper

Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer

verfasst von: Mats Lambe, Annette Wigertz, Hans Garmo, Göran Walldius, Ingmar Jungner, Niklas Hammar

Erschienen in: Cancer Causes & Control | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Epidemiological evidence indicates that individuals with type 2 diabetes are at an increased risk of cancer. Elevated glucose levels, below the diagnostic threshold for diabetes, have also been suggested to be associated with increased cancer risks.

Methods

We investigated possible associations between glucose levels and the risk of breast, endometrial, and ovarian cancer in a cohort of more than 230,000 women, for which information on outcome and potential confounders was obtained by record linkage to population-based registers.

Results

Diabetes was associated with an increased risk of postmenopausal breast cancer (HR = 1.22, 95% CI 1.04–1.43). An indication of a slightly elevated breast cancer risk was also found in postmenopausal women with impaired glucose metabolism (HR = 1.11, 95% CI 0.96–1.28). Diabetes (HR = 1.46, 95% CI 1.09–1.96) and impaired glucose metabolism (HR = 1.41, 95% CI 1.08–1.85) were associated with an increased risk of endometrial cancer. No associations were found between glucose levels and ovarian cancer risk. Following adjustment for BMI, estimates were attenuated for endometrial cancer, while point estimates for breast and ovarian cancer remained essentially unchanged.

Conclusions

Our results indicate that glucose levels below the diagnostic threshold for diabetes modify the risk not only of endometrial cancer but possibly also of postmenopausal breast cancer.
Literatur
1.
Zurück zum Zitat Strickler HD, Wylie-Rosett J, Rohan T et al (2001) The relation of type 2 diabetes and cancer. Diabetes Technol Ther 3:263–274PubMedCrossRef Strickler HD, Wylie-Rosett J, Rohan T et al (2001) The relation of type 2 diabetes and cancer. Diabetes Technol Ther 3:263–274PubMedCrossRef
2.
Zurück zum Zitat Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674–1685PubMedCrossRef Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674–1685PubMedCrossRef
3.
Zurück zum Zitat Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083PubMedCrossRef Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083PubMedCrossRef
4.
Zurück zum Zitat El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380PubMedCrossRef El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380PubMedCrossRef
5.
Zurück zum Zitat Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef
6.
Zurück zum Zitat Friberg E, Orsini N, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365–1374PubMedCrossRef Friberg E, Orsini N, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365–1374PubMedCrossRef
7.
Zurück zum Zitat Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A (2008) Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 98:1582–1585PubMedCrossRef Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A (2008) Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 98:1582–1585PubMedCrossRef
8.
Zurück zum Zitat Saltzman BS, Doherty JA, Hill DA et al (2008) Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol 167:607–614PubMedCrossRef Saltzman BS, Doherty JA, Hill DA et al (2008) Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol 167:607–614PubMedCrossRef
9.
Zurück zum Zitat Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6:103–111PubMedCrossRef Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6:103–111PubMedCrossRef
10.
Zurück zum Zitat Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862PubMedCrossRef Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862PubMedCrossRef
11.
Zurück zum Zitat Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86:S823–S835PubMed Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86:S823–S835PubMed
12.
Zurück zum Zitat Adler AI, Weiss NS, Kamb ML, Lyon JL (1996) Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States). Cancer Causes Control 7:475–478PubMedCrossRef Adler AI, Weiss NS, Kamb ML, Lyon JL (1996) Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States). Cancer Causes Control 7:475–478PubMedCrossRef
13.
Zurück zum Zitat Parazzini F, Moroni S, La Vecchia C, Negri E, dal Pino D, Bolis G (1997) Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 33:1634–1637PubMedCrossRef Parazzini F, Moroni S, La Vecchia C, Negri E, dal Pino D, Bolis G (1997) Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 33:1634–1637PubMedCrossRef
14.
Zurück zum Zitat Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365PubMedCrossRef Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365PubMedCrossRef
15.
Zurück zum Zitat Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO (2002) Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control 13:759–764PubMedCrossRef Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO (2002) Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control 13:759–764PubMedCrossRef
16.
Zurück zum Zitat Muti P, Quattrin T, Grant BJ et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11:1361–1368PubMed Muti P, Quattrin T, Grant BJ et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11:1361–1368PubMed
17.
Zurück zum Zitat Furberg AS, Thune I (2003) Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 104:669–676PubMedCrossRef Furberg AS, Thune I (2003) Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 104:669–676PubMedCrossRef
18.
Zurück zum Zitat Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157:1092–1100PubMedCrossRef Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157:1092–1100PubMedCrossRef
19.
Zurück zum Zitat Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. Jama 293:194–202PubMedCrossRef Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. Jama 293:194–202PubMedCrossRef
20.
Zurück zum Zitat Rapp K, Schroeder J, Klenk J et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49:945–952PubMedCrossRef Rapp K, Schroeder J, Klenk J et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49:945–952PubMedCrossRef
21.
Zurück zum Zitat Dankner R, Chetrit A, Segal P (2007) Glucose tolerance status and 20 year cancer incidence. Isr Med Assoc J 9:592–596PubMed Dankner R, Chetrit A, Segal P (2007) Glucose tolerance status and 20 year cancer incidence. Isr Med Assoc J 9:592–596PubMed
22.
Zurück zum Zitat Stattin P, Bjor O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30:561–567PubMedCrossRef Stattin P, Bjor O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30:561–567PubMedCrossRef
23.
Zurück zum Zitat Stocks T, Rapp K, Bjorge T et al (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6(12):e1000201PubMedCrossRef Stocks T, Rapp K, Bjorge T et al (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6(12):e1000201PubMedCrossRef
24.
Zurück zum Zitat Manjer J, Kaaks R, Riboli E, Berglund G (2001) Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo preventive project. Eur J Cancer Prev 10:33–42PubMedCrossRef Manjer J, Kaaks R, Riboli E, Berglund G (2001) Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo preventive project. Eur J Cancer Prev 10:33–42PubMedCrossRef
25.
Zurück zum Zitat Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156:349–352PubMedCrossRef Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156:349–352PubMedCrossRef
26.
Zurück zum Zitat Kabat GC, Kim M, Caan BJ et al (2009) Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125:2704–2710PubMedCrossRef Kabat GC, Kim M, Caan BJ et al (2009) Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125:2704–2710PubMedCrossRef
27.
Zurück zum Zitat Cust AE, Kaaks R, Friedenreich C et al (2007) Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European prospective investigation into cancer and nutrition (EPIC). Endocr Relat Cancer 14:755–767PubMedCrossRef Cust AE, Kaaks R, Friedenreich C et al (2007) Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European prospective investigation into cancer and nutrition (EPIC). Endocr Relat Cancer 14:755–767PubMedCrossRef
28.
Zurück zum Zitat Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026–2033PubMedCrossRef Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026–2033PubMedCrossRef
29.
Zurück zum Zitat Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish cancer register: a sample survey for year 1998. Acta oncologica (Stockholm, Sweden) 48:27–33CrossRef Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish cancer register: a sample survey for year 1998. Acta oncologica (Stockholm, Sweden) 48:27–33CrossRef
30.
Zurück zum Zitat Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E (1998) Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-international federation of clinical chemistry first international reference materials. Clin Chem 44:1641–1649PubMed Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E (1998) Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-international federation of clinical chemistry first international reference materials. Clin Chem 44:1641–1649PubMed
32.
Zurück zum Zitat Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev 8:915–928CrossRef Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev 8:915–928CrossRef
34.
Zurück zum Zitat Bjorge T, Lukanova A, Jonsson H et al (2010) Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 19:1737–1745PubMedCrossRef Bjorge T, Lukanova A, Jonsson H et al (2010) Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 19:1737–1745PubMedCrossRef
35.
Zurück zum Zitat Hemminki K, Li X, Sundquist J, Sundquist K (2010) Risk of cancer following hospitalization for type 2 diabetes. Oncologist 15:548–555PubMedCrossRef Hemminki K, Li X, Sundquist J, Sundquist K (2010) Risk of cancer following hospitalization for type 2 diabetes. Oncologist 15:548–555PubMedCrossRef
36.
Zurück zum Zitat Hamajima N, Hirose K, Tajima K et al (2002) Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87:1234–1245PubMedCrossRef Hamajima N, Hirose K, Tajima K et al (2002) Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87:1234–1245PubMedCrossRef
37.
Zurück zum Zitat Magnusson C, Wedren S, Rosenberg LU (2007) Cigarette smoking and breast cancer risk: a population-based study in Sweden. Br J Cancer 97:1287–1290PubMedCrossRef Magnusson C, Wedren S, Rosenberg LU (2007) Cigarette smoking and breast cancer risk: a population-based study in Sweden. Br J Cancer 97:1287–1290PubMedCrossRef
38.
Zurück zum Zitat Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM (2006) Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 103:1122–1129PubMedCrossRef Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM (2006) Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 103:1122–1129PubMedCrossRef
39.
Zurück zum Zitat Zhou B, Yang L, Sun Q et al (2008) Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 121:501–508PubMedCrossRef Zhou B, Yang L, Sun Q et al (2008) Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 121:501–508PubMedCrossRef
40.
Zurück zum Zitat Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625PubMedCrossRef Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625PubMedCrossRef
41.
Zurück zum Zitat Smith U, Gale EA (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708PubMedCrossRef Smith U, Gale EA (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708PubMedCrossRef
42.
Zurück zum Zitat Pollak M (2010) Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 3:1060–1065CrossRef Pollak M (2010) Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 3:1060–1065CrossRef
43.
Zurück zum Zitat Misra A (2009) Prevention of type 2 diabetes: the long and winding road. Lancet 374:1655–1656PubMedCrossRef Misra A (2009) Prevention of type 2 diabetes: the long and winding road. Lancet 374:1655–1656PubMedCrossRef
Metadaten
Titel
Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer
verfasst von
Mats Lambe
Annette Wigertz
Hans Garmo
Göran Walldius
Ingmar Jungner
Niklas Hammar
Publikationsdatum
01.08.2011
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 8/2011
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9794-8

Weitere Artikel der Ausgabe 8/2011

Cancer Causes & Control 8/2011 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.